Latest News

It was a historic stretch of time for the biotech.

This investment offers a terrific combination of likely price appreciation along with dividend income.

This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.

This error could really trip you up.

The company crushed bottom-line estimates in its final quarter of 2025.

This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.

Investors are concerned about restrictive regulations against social media companies.

Most investors hit the $109,000 TFSA milestone with consistent contributions, not one big deposit.

Could Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode.

The outcome for investors could be more complex than it seems.

The war in Iran is driving widespread selling in the stock market.

The performance came from an unlikely source for this company.

Trader barriers are increasing import prices for most businesses, including e.l.f.

Drivers are paying higher fuel prices.

Explore the strengths and use cases of AI image generators in marketing. See a four-step framework for creating efficient, crisp, and multipurpose visuals.

One analyst tracking the stock shaved $10 off his price target.

Specializing in CNS therapies, this biopharma firm reported a notable insider sale amid a year of strong stock performance.

What’s the first thing that you are thinking about if you want to start your journey with trading? Chances are high that safety is among the top factors you are considering when deciding whether starting to trade is a good idea. If that sounds like you, we must congratulate you, as you have taken a [...]

Learn how trade tensions impact financial markets, from tariffs to sanctions, and what it means for energy and commodity investments.

Specializing in branded and generic pharmaceuticals, this sector player reported a notable insider sale amid a stable transaction pattern.

A “pay me first” portfolio focuses on dividends that are supported by real cash flow, not headline yields.

It underwent a rather surprising C-suite change.

How does a divided yield topping 5% sound?